electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.
IPO Year: 2018
Exchange: NASDAQ
Website: electrocore.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/19/2022 | $3.00 → $2.75 | Buy | HC Wainwright & Co. |
7/27/2021 | $3.00 | Buy | Ladenburg Thalmann |
ROCKAWAY, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the Air Force Research Laboratories (AFRL) presented new results supporting the ability of electroCore's TAC-STIM (nVNS) to accelerate pilot training. The presentation titled "Accelerating Sensorimotor Learning in A Flight Training Simulation Using Transcutaneous Vagus Nerve Stimulation" was presented on Tuesday, August 26th at the 2024 Medical Health System Research Symposium in Orlando, FL. by Dr. Justin Estepp of the Human Effectiveness Directorate of the United States Air Force Research Laboratories (AFRL). The presenta
ROCKAWAY, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the 26th Annual H.C. Wainwright Global Investment Conference taking place in New York City on September 9-11, 2024. Dan Goldberger, the company's Chief Executive Officer, will participate in a fireside chat on Wednesday, September 11th, at 12:00 PM ET. Mr. Goldberger will also be available for 1x1 meetings the same day. For more information regarding the conference and to register, please visit the conference page here. About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectron
LONDON, UNITED KINGDOM / ACCESSWIRE / September 4, 2024 / Ecora Resources PLC (LSE/TSX:ECOR) announces half year results for the six months ended 30 June 2024 which are available on both the Group's website at www.ecora-resources.com and on SEDAR at www.sedar.com. Ecora is the leading royalty company focused on supporting the supply of industrial commodities essential to creating a sustainable future. The Group has a portfolio which combines volume growth in 2024 and 2025 from its currently producing royalty portfolio with an extensive pipeline of high-quality development projects that are expected to drive material medium term revenue growth.Marc Bishop Lafleche, Chief Executive Officer of
ROCKAWAY, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company's CEO, Dan Goldberger, is scheduled to participate in the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference August 12 - 13, 2024. Please contact Needham to schedule a 1x1 meeting. In addition, Brian Posner, CFO of electroCore, Inc. is scheduled to attend the 44th Annual Canaccord Genuity Growth Conference taking place at InterContinental Hotel in Boston, MA. electroCore will host 1x1 investor meetings on August 13, 2024. Please contact Canaccord Genuity to schedule a 1x1 meeting. About electroCore
Seventh consecutive record quarterly net sales of $6.1 million, an increase of 73% over second quarter 2023 Company to host a conference call and webcast today, August 7, 2024 at 4:30 PM EST ROCKAWAY, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced second quarter 2024 financial results. Recent Highlights •Net loss of $2.7 million, a decrease of 46% over second quarter 2023 •Launched our direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus™ •Raised approximately $9.0 million in a Registered Direct Offering and Concurrent Private Placements priced
ROCKAWAY, N.J., Aug. 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the "Company"), (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that on August 1, 2024, Stephen Smith joined electroCore as the Company's VP, Quality, Regulatory, and Compliance, and the Compensation Committee of electroCore's Board of Directors granted 10,000 restricted stock units ("RSUs") to Mr. Smith in connection with the commencement of his employment. The RSUs were granted as an inducement material to Mr. Smith's commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). 33% of the RSUs will vest on each of the first, second and third anniversaries of the d
ROCKAWAY, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the Air Force Research Laboratories (AFRL) published a paper entitled "Transcutaneous Cervical Vagus Nerve Stimulation Enhances Second-Language Vocabulary Acquisition While Simultaneously Mitigating Fatigue and Promoting Focus" in Scientific Reports on July 26, 2024 (Link). The paper is based on a study that was conducted at the Defense Language Institute (DLI) in Monterey, CA, the U.S. Department of Defense's premier language school. The study was supported by Defense Advanced Research Projects Agency (DARPA)/AFRL within th
ROCKAWAY, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2024, after the close of the market on Wednesday, August 7, 2024. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, August 7, 4:30 PM EDTDial-In: 877-407-8835 / +1 201-689-8779Conference ID: 13744119Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving heal
ROCKAWAY, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, is thrilled to announce the Commercial Off the Shelf (COTS) availability of the next generation TAC-STIM™, a non-invasive vagus nerve stimulator (nVNS) designed in partnership with the US military to enhance human performance exclusively for active-duty military use. TAC-STIM is a cutting-edge device that can accelerate learning and improve mood and cognitive performance. TAC-STIM is a portable, easy-to-use tool that leverages electroCore's patented technology to deliver precise and effective vagus nerve stimulation, helping war fighters and
ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the preliminary additions list for inclusion in the Russell Microcap® Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on May 24, 2024. "We are pleased to have been selected to join the Russell Microcap® Index," said Brian Posner, Chief Finan
**Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report
- SEC Filing
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, is thrilled to announce the Commercial Off the Shelf (COTS) availability of the next generation TAC-STIM™, a non-invasive vagus nerve stimulator (nVNS) designed in partnership with the US military to enhance human performance exclusively for active-duty military use. TAC-STIM is a cutting-edge device that can accelerate learning and improve mood and cognitive performance. TAC-STIM is a portable, easy-to-use tool that leverages electroCore's patented technology to deliver precise and effective vagus nerve stimulation, helping war fighters and operators learn new tasks, increase readiness and mitig
**Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.61) by 13.11 percent. This is a 57.26 percent increase over losses of $(1.24) per share from the same period last year. The company reported quarterly sales of $5.443 million which beat the analyst consensus estimate of $4.767 million by 14.18 percent. This is a 95.79 percent increase over sales of $2.780 million the same period last year.
Gainers CytomX Therapeutics (NASDAQ:CTMX) stock increased by 87.1% to $7.84 during Wednesday's after-market session. The market value of their outstanding shares is at $534.1 million. As per the press release, Q1 earnings came out today. ZimVie (NASDAQ:ZIMV) shares increased by 17.03% to $18.0. The company's market cap stands at $489.9 million. The company's, Q1 earnings came out today. Aesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 15.0% to $0.53. The market value of their outstanding shares is at $25.2 million. electroCore (NASDAQ:ECOR) shares rose 11.98% to $7.85. The market value of their outstanding shares is at $47.1 million. The company's, Q1 earnings came out today.
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO). The two patents were issued on April 2, 2024, and relate to electroCore's non-invasive vagus nerve stimulation (nVNS) technology: US Patent No. 11,944,815 entitled "Non-Invasive Nerve Stimulation with Mobile Device" generally relates to a system for transcutaneously stimulating a nerve in a patient that includes a downloadable software application configured to wirelessly transmit a therapy regimen to a stimulator. The therapy regimen comprises generating an electrical signa
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates electroCore (NASDAQ:ECOR) with a Buy and maintains $15 price target.
ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the preliminary additions list for inclusion in the Russell Microcap® Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on May 24, 2024. "We are pleased to have been selected to join the Russell Microcap® Index," said Brian Posner, Chief Finan
FAIRFAX, Va. and TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly"), a pioneering artificial intelligence ("AI") company developing innovative neuroscientific solutions to improve outcomes for patients with mental illnesses and neurological disorders, today announced the appointment of Brian M. Posner to its Board of Directors upon closing of its planned merger with WaveDancer, Inc. ("WaveDancer") (NASDAQ:WAVD). Firefly has entered into a definitive agreement and plan of merger (as amended, the "Merger Agreement") with WaveDancer, which has been approved by the stockholders of both companies and both companies are working towards meeting the final closing cond
ROCKAWAY, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Julie Bruzzone Goldstein and Tricia Wilber to the company's Board of Directors effective March 15, 2022. The Company also announced that effective March 4, 2022, Dr. Stephen Ondra is resigning from the Board to focus on his new role as Chief Medical Advisor at MITRE, and Michael Atieh will not be standing for re-election to the Board at the 2022 Annual General Meeting. "Ms. Goldstein and Ms. Wilber are successful business leaders with proven track records, and I am pleased to welcome them to our Board," said Peter Cuneo
Full year 2020 revenue expected at the upper end of previously announced guidance range of $3.3M - $3.5M; greater than 40% growth over full year 2019 revenue of $2.4M Net cash used for the fourth quarter 2020 of $3.7 million, compares favorably to previously announced guidance of $4M December 31, 2020 cash and cash equivalents of $22.6M BASKING RIDGE, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select unaudited financial guidance for the fourth quarter. “Notwithstanding the resurgence of COVID-19 case counts which began midway through the fourth qu
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
SC 13D/A - electroCore, Inc. (0001560258) (Subject)
SC 13G/A - electroCore, Inc. (0001560258) (Subject)
SC 13D - electroCore, Inc. (0001560258) (Subject)
SC 13G - electroCore, Inc. (0001560258) (Subject)
SC 13G/A - electroCore, Inc. (0001560258) (Subject)
SC 13G/A - electroCore, Inc. (0001560258) (Subject)
SC 13G - electroCore, Inc. (0001560258) (Subject)
SC 13G/A - electroCore, Inc. (0001560258) (Subject)
SC 13G - electroCore, Inc. (0001560258) (Subject)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
4 - electroCore, Inc. (0001560258) (Issuer)
LONDON, UNITED KINGDOM / ACCESSWIRE / September 4, 2024 / Ecora Resources PLC (LSE/TSX:ECOR) announces half year results for the six months ended 30 June 2024 which are available on both the Group's website at www.ecora-resources.com and on SEDAR at www.sedar.com. Ecora is the leading royalty company focused on supporting the supply of industrial commodities essential to creating a sustainable future. The Group has a portfolio which combines volume growth in 2024 and 2025 from its currently producing royalty portfolio with an extensive pipeline of high-quality development projects that are expected to drive material medium term revenue growth.Marc Bishop Lafleche, Chief Executive Officer of
ROCKAWAY, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2024, after the close of the market on Wednesday, August 7, 2024. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, August 7, 4:30 PM EDTDial-In: 877-407-8835 / +1 201-689-8779Conference ID: 13744119Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving heal
Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023Company to host a conference call and webcast today, May 8, 2024 at 4:30 PM EST ROCKAWAY, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced first quarter 2024 financial results. Recent Highlights Record revenue of $5.4 million, an increase of 96% over first quarter 2023Launched our direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus™ First Quarter 2024 Financial Results For the quarter ended March 31, 2024, electroCore reported net sales of $5.4 million c
ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of the market on Wednesday, May 8, 2024. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, May 8, 4:30 PM EDTDomestic: 877-407-8835International: located hereConference ID: 13744118Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving heal
ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023, after the close of the market on Wednesday, March 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions. Wednesday, March 13, 4:30 PM ESTDomestic: 877-407-8835International: located hereConference ID: 13744117Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicat
ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2023, after the close of the market on Wednesday, November 8, 2023. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions. Wednesday, November 8, 2023, 4:30 PM ESTDomestic: 877-407-8835International: located hereConference ID: 13739201Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicat
ROCKAWAY, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2023, after the close of the market on Wednesday, August 9, 2023. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, August 9, 2023, 4:30 PM EDTDomestic: 877-407-8835International: +1 201-689-8779Conference ID: 13739200Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to
Record first quarter 2023 net sales of $2.8 million, approximately 46% over first quarter 2022 Company to host a conference call and webcast today, May 3, 2023, at 4:30 PM EDT ROCKAWAY, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced first quarter 2023 financial results and provided an operational update. First Quarter 2023 and Recent Highlights Record revenue of $2.8 million, an increase of approximately 46% over first quarter 2022The Air Force Research Laboratories reported human performance data from its study suggesting that gammaCore™ non-invasive vagus nerve stimulatio
ROCKAWAY, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2023, after the close of the market on Wednesday, May 3, 2023. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, May 3, 2023, 4:30 PM EDTDomestic: 877-269-7756International: 201-689-7817Conference ID: 13738144Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health thr
Record full year 2022 net sales of $8.6 million increased 58% over $5.5 million for full year 2021 Company to host conference call and webcast today, March 8, 2023 at 4:30pm EST ROCKAWAY, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) (the "Company"), a commercial-stage bioelectronic medicine and wellness company, today announced fourth quarter and full year 2022 financial results and provided an operational update. Fourth Quarter 2022 and Recent Highlights Reported record full year 2022 net sales of $8.6 million, representing an increase of 58% over $5.5 million for full year 2021Fourth quarter net sales of $2.6 million, an increase of 72% over $1.5 million f
HC Wainwright & Co. reiterated coverage of electroCore with a rating of Buy and set a new price target of $2.75 from $3.00 previously
Ladenburg Thalmann initiated coverage of electroCore with a rating of Buy and set a new price target of $3.00
Maxim Group resumed coverage of electroCore with a rating of Buy and set a new price target of $3.00
8-K - electroCore, Inc. (0001560258) (Filer)
10-Q - electroCore, Inc. (0001560258) (Filer)
8-K - electroCore, Inc. (0001560258) (Filer)
D - electroCore, Inc. (0001560258) (Filer)
424B3 - electroCore, Inc. (0001560258) (Filer)
EFFECT - electroCore, Inc. (0001560258) (Filer)
S-1/A - electroCore, Inc. (0001560258) (Filer)
DEF 14A - electroCore, Inc. (0001560258) (Filer)
8-K - electroCore, Inc. (0001560258) (Filer)
S-1 - electroCore, Inc. (0001560258) (Filer)